National Holdings Corporation (NHLD) News
Filter NHLD News Items
NHLD News Results
|Event/Time||Symbol||Company||News Detail||Start||End||Change||POWR Rating|
|Loading, please wait...|
Latest NHLD News From Around the Web
Below are the latest news stories about National Holdings Corp that investors may wish to consider to help them evaluate NHLD as an investment opportunity.
ORLANDO, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Franchise Group, Inc. (NASDAQ: FRG) (“Franchise Group” or the “Company”) today announced the closing of its previously announced underwritten registered public offering of 1,200,000 shares of its 7.50% Series A Cumulative Perpetual Preferred Stock, par value $0.01 per share and liquidation preference of $25.00 per share (the “Preferred Stock”), at an initial public offering price of $25.00 per share. The offering resulted in net proceeds of approximately $29.1 million after deducting underwriting discounts and commissions, but before deducting expenses and the structuring fee. The Company expects to use the net proceeds of this offering for general corporate purposes, including funding future acquisitions and investments. The underwriters hav...
Tesla is a 'cult stock,' according to this strategist 'nothing changed fundamentally after the stock split'
Art Hogan, Chief Market Strategist at National, joins Yahoo Finance’s The First Trade with Alexis Christoforous and Brian Sozzi to discuss what's moving the markets on Thursday morning. Hogan also weighs in on the future of real estate, especially in major cities.
SANTA MONICA, Calif., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Super League Gaming (Super League or the Company) (Nasdaq: SLGG), a global leader in competitive video gaming and esports entertainment for everyday players around the world, today announced the pricing of an underwritten public offering of 4,540,541 shares of its common stock at a public offering price of $1.85 per share. Gross proceeds from the offering, before underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $8.4 million. In addition, Super League has granted the underwriter a 30-day option to purchase up to an additional 681,081 shares of common stock at the same public offering price per share, to cover over-allotments, if any. Super League currently intends to use the n...
National Bank of Canada's profit was steady in its fiscal third quarter as the bank set aside far less cash for loans that could go bad.
After recording more than 100 days of COVID-free bliss, New Zealand Prime Minister Jacinda Adern is headed for a stomping victory at next month’s general election: In July support for Prime Minister Jacinda Ardern’s Labour Party was at 53.5% down 1% since June, but still more than double the support for National on 26.5%, down
The Association of Public Health Laboratories has announced it is working with Apple, Google, and Microsoft to launch a national server that will securely store COVID-19 exposure notification data.
COS COB, Conn., July 17, 2020 -- Chicken Soup for the Soul Entertainment Inc. (Nasdaq: CSSE) (the “Company”), one of the largest operators of streaming advertising-supported.
COS COB, Conn., July 13, 2020 -- Chicken Soup for the Soul Entertainment Inc. (Nasdaq: CSSE) (the “Company”), one of the largest operators of streaming advertising-supported.
NEW YORK--(BUSINESS WIRE)--JPMorgan Chase & Co. (NYSE: JPM) (“JPMorgan Chase” or the “Firm”) announced today that it has completed the 2020 Comprehensive Capital Analysis and Review (“CCAR”) stress test process. Information can be found on the Firm’s Investor Relations website at www.jpmorganchase.com/press-releases. The Firm also announced today that it has released the results of its company-run 2020 Dodd-Frank Act Stress Test for JPMorgan Chase & Co. and JPMorgan Chase Bank, National
The gross proceeds to Catalyst from this offering were approximately $30.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Catalyst. All of the shares in the offering were sold by Catalyst. Catalyst anticipates using the net proceeds from this offering for general corporate purposes, which may include research and development activities in its complement program, clinical and manufacturing activities for marzeptacog alfa and dalcinonacog alfa, other research and development activities, capital expenditures, selling, general and administrative costs, facilities expansion, and to meet working capital needs.